{"nctId":"NCT03031782","briefTitle":"Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)","startDateStruct":{"date":"2017-05-23","type":"ACTUAL"},"conditions":["Juvenile Psoriatic Arthritis","Enthesitis-related Arthritis"],"count":86,"armGroups":[{"label":"Treatment Period 2 - active","type":"EXPERIMENTAL","interventionNames":["Drug: secukinumab"]},{"label":"Treatment Period 2 - placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: placebo"]}],"interventions":[{"name":"secukinumab","otherNames":["AIN457"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Confirmed diagnosis of Enthesitis-related arthritis (ERA) or Juvenile psoriatic arthritis (JPsA) according to the International League of Associations for Rheumatology (ILAR) classification criteria of at least 6 months duration.\n2. Active disease (ERA or JPsA) defined as having both:\n\n   * at least 3 active joints\n   * at least 1 site of active enthesitis at baseline or documented by history.\n3. Inadequate response (at least 1 month) or intolerance to at least 1 nonsteroidal anti-inflammatory drugs(NSAID)\n4. Inadequate response (at least 2 months) or intolerance to at least 1 Disease-modifying antirheumatic drugs (DMARD)\n5. No concomitant use of second line agents such as disease-modifying and/or immunosuppressive drugs.\n\nExclusion Criteria:\n\n1. Patients fulfilling any ILAR diagnostic JIA category other than ERA or JPsA.\n2. Patients who have ever received biologic immunomodulating agents\n3. Patients taking any non-biologic DMARD except for MTX (or sulfasalazine for ERA patients only).\n4. Patients with active uncontrolled inflammatory bowel disease or active uncontrolled uveitis.\n\nOther protocol-defined inclusion/exclusion criteria apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Experiencing a Flare During Treatment Period 2","description":"Survival analysis of time to flare in treatment period 2 (TP2) FAS2\n\nSubjects are either ERA or JPsA","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30/50/70/90/100 Response at Week 12 - by JIA Category","description":"Summary of JIA ACR 30/50/70/90/100 for all subjects and each JIA category - TP1 (FAS1)\n\nThe adapted ACR Pediatric 30/50/70/90/100 criteria was used to determine efficacy defined as improvement from baseline of at least 30/50/70/90/100% respectively in at least 3 of the following 6 components\n\n* Physician's Global Assessment of disease activity on a 0-100 mm VAS from 0 mm = no disease activity to 100 mm = very severe disease activity.\n* Parent's or patient's Global Assessment of Subject's overall wellbeing on a 0-100 mm VAS from 0 mm= very well to 100 mm= very poor.\n* Functional ability: Childhood Health Assessment Questionnaire (CHAQ©)\n* Number of joints with active arthritis using the ACR definition (The ACR definition of active arthritis is any joint with swelling, or in the absence of swelling, limitation of motion accompanied by either pain on motion or tenderness not due to deformity)\n* Number of joints with limitation of motion\n* Laboratory measure of inflammation: CRP (mg/L)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.3","spread":null},{"groupId":"OG001","value":"96.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.4","spread":null},{"groupId":"OG001","value":"96.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.5","spread":null},{"groupId":"OG001","value":"21.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30/50/70/90/100 Response at Week 12 - Total","description":"Summary of JIA ACR 30/50/70/90/100 for all subjects - TP1 (FAS1)\n\nThe adapted ACR Pediatric 30/50/70/90/100 criteria was used to determine efficacy defined as improvement from baseline of at least 30/50/70/90/100% respectively in at least 3 of the following 6 components\n\n* Physician's Global Assessment of disease activity on a 0-100 mm VAS from 0 mm = no disease activity to 100 mm = very severe disease activity.\n* Parent's or patient's Global Assessment of Subject's overall wellbeing on a 0-100 mm VAS from 0 mm= very well to 100 mm= very poor.\n* Functional ability: Childhood Health Assessment Questionnaire (CHAQ©)\n* Number of joints with active arthritis using the ACR definition (The ACR definition of active arthritis is any joint with swelling, or in the absence of swelling, limitation of motion accompanied by either pain on motion or tenderness not due to deformity)\n* Number of joints with limitation of motion\n* Laboratory measure of inflammation: CRP (mg/L)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline for JIA ACR Core Components in TP1","description":"Summary of JIA ACR core components for all subjects and each JIA category - Treatment period 1\n\nNegative percent change indicates improvement\n\nPhysician global assessment of disease activity (VAS mm) 0 (no disease activity) - 100 (very severe); Parent or subject global assessment of overall well-being (VAS mm) 0 (very well) - 100 (very poor); CHAQ (Childhood Health Assessment Questionnaire) 0 - 3 (most severe); Number of joints with active arthritis 0 - 73; Number of joints with limited range of motion 0 - 69.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-77.4","spread":"22.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-53.1","spread":"58.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-53.776","spread":"70.5034"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-79.3","spread":"34.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-72.5","spread":"38.19"}]}]}]},{"type":"SECONDARY","title":"Percent Change in C-reactive Protein Standardized Value (mg/L)","description":"Median Percent Change from baseline for C-reactive protein standardized value (mg/L)","paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.587","spread":"227.6901"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Juvenile Arthritis Disease Activity Score (JADAS) Score","description":"JADAS change from baseline for all subjects in Treatment period 1. JADAS-27 (Juvenile Arthritis Disease Activity Score in 27 joints) ranges from 0 to 57 and JADAS-71 ranges from 0 to 101 (higher scores indicate more disease activity).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.487","spread":"7.2262"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.403","spread":"9.7300"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Enthesitis Events - TP1 (FAS1)","description":"Enthesitis swollen joint count range is 0-16. Zero is worst, and 16 is best\n\nA total of 16 entheseal sites were assessed for the presence or absence of tenderness of enthesitis.\n\nThis is the mean (SD) enthesitis count (range 0-16) for FAS subjects\n\nA zero score means no enthesitis, so a zero score is better for the patient","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"2.31"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Dactylitis Count","description":"Summary of total dactylitis count for all subjects - TP1 (FAS1)\n\nTotal dactylitis count ranges from 0 to 20. A zero score means no dactylitis, so a zero score is better for the patient","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.83"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Anti-secukinumab Anitbodies","description":"Blood samples for immunogenicity (anti-AIN457 antibodies) were taken pre-dose at the scheduled time points. In addition, if a subject discontinued from the study at any time, he/she provided a sample at the last visit. All blood samples were taken by either direct venipuncture or an indwelling cannula inserted in a forearm vein. An Electrochemiluminescence method was used for the detection of potential anti-secukinumab antibody formation.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Secukinumab Serum Concentration","description":"Summary of pharmacokinetic concentrations - Treatment period 1","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.9","spread":"12.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.6","spread":"11.2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Inactive Disease Status for All Subjects - TP1 (FAS1)","description":"Summary of inactive disease status for all subjects - TP1 (FAS1)\n\nClinical inactive disease definition was adapted from the JIA ACR criteria.\n\nAll were required to be met:\n\n* No joints with active arthritis\n* No uveitis\n* CRP value within normal limits for the laboratory where tested or, if elevated, not attributable to JIA\n* Physician's global assessment of disease activity score ≤ 10mm\n* Duration of morning stiffness attributable to JIA ≤15 min","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":48},"commonTop":["Nasopharyngitis","Nausea","Upper respiratory tract infection","Diarrhoea","Cough"]}}}